ArticleBMC microbiology2025
Longitudinal dysbiosis of gut bacteriome and mycobiome in patients with severe acute pancreatitis and its association with mortality.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Longitudinal dynamics of gut microbiota and mycobiota in pneumonia-derived sepsis: evidence of taxonomic stability and trans-kingdom network reorganization.Gut pathogens · 2026Article
- Application value of blood-brain barrier and peripheral inflammatory markers in early diagnosis of pancreatic encephalopathy in severe acute pancreatitis.Frontiers in neuroscience · 2026Article
- Beyond the Pancreas: The Gut Microbiota in Acute Pancreatitis - From Mechanisms to Therapeutic Perspectives.Clinical and experimental gastroenterology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe dysbiosis of gut microbiome is known to have a significant impact on the progression of sever acute pancreatitis (SAP). This study intends to investigate the alteration of gut microbiome in SAP patients during hospitalization and its association with mortality. Bacterial and fungal compositions of the fecal microbiota were determined via 16S and ITS1 sequencing, respectively.
resultsOur findings indicated that SAP patients exhibited bacterial and fungal dysbiosis either at the time of admission or within the first 72 h of admission prior to any antibiotic treatment, characterized by reduced biodiversity, lower abundances of Blautia, Bifidobacterium, and increased Escherichia-Shigella, Enterococcus, and Candida. The overall microbiome was partially restored post-treatment in survivors, including commensal Bifidobacterium enhancement. In contrast, non-survivors experienced sustained perturbations during hospitalization, with over-representation of pathogenic Enterococcus and Candida. A classifier based on 20 optimal bacteria markers showed superior efficiency for predicting mortality. Interestingly, the abundances of Acinetobacter, Klebsiella and Candida were considerably elevated in the gut of patients who subsequently developed infectious complications.
conclusionsOur study provided a comprehensive profile of gut bacteriome and mycobiome in SAP patients and identified the temporal trajectory alterations of microbiome associated with mortality. These findings underscore the importance of early recognition of pathobiome states and the potential role for the modulation of microbiota during the development of SAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.